
Oncology NEWS International
- Oncology NEWS International Vol 11 No 8
- Volume 11
- Issue 8
Medicaid Gives New Protections to Beneficiaries in Managed Care Plans
WASHINGTON-Final regulations issued by the Department of Health and Human Services guarantee Medicaid beneficiaries enrolled in managed care plans the same protections granted to people in private plans under legislation pending
WASHINGTONFinal regulations issued by the Department of Health and Human Services guarantee Medicaid beneficiaries enrolled in managed care plans the same protections granted to people in private plans under legislation pending in Congress. The regulations take effect Aug. 13, and states and health plans have 1 year to come into full compliance.
The rules guarantee emergency room care, a second opinion when needed, and a timely right to appeal decisions. However, each state will decide how to implement patient protection and use managed care in its Medicaid plan.
Articles in this issue
almost 24 years ago
Prostate Cancer Cell Line Vaccine Promising in Phase II Trialalmost 24 years ago
MoAb Targeting Death Receptor in Breast Canceralmost 24 years ago
Hanford I-131 Releases Did Not Increase Thyroid Cancer Riskalmost 24 years ago
Chemo/Rituximab Is Effective as First-Line CLL Therapyalmost 24 years ago
Diagnostic Dilemmaalmost 24 years ago
Viral Agent ONYX-015 Targets p53-Deficient Cancer Cellsalmost 24 years ago
Program Educates Teens About Testicular Cancer Self-Examalmost 24 years ago
Better Colon Cancer Imaging With PET/CT Than With PET Alonealmost 24 years ago
Delayed Lung Cancer Screening Trial to Begin Enrollment 50,000 Subjectsalmost 24 years ago
Results Similar With Weekly or Every-3-Week Irinotecan Dosing RegimensNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
















































